Preventing liver and heart disease through lifestyle changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to prevent non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) by implementing a lifestyle intervention program called MAUCO+. The study will involve 300 participants who will be randomly assigned to either a control group receiving standard recommendations or an experimental group receiving tailored exercise and dietary interventions. The goal is to improve physical fitness, body composition, and metabolic health through supervised exercise and an anti-inflammatory diet. The trial specifically targets individuals with gallstone disease and varying degrees of NAFLD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* With and without gallstones disease
* With various degrees of NAFLD (none too severe)

Exclusion Criteria:

* Any significant comorbidity or physical limitation to undergo resistance exercise program
* Use of medications that alter muscle mass (e.g., corticosteroids)
* History of hepatitis B or C
* Use of hepatotoxic drugs

Where it's running

• Centro MAUCO+
  Molina, Maule Region, Chile Recruiting

Study contacts

• Principal investigator: Catterina Ferreccio, MD — Pontificia Universidad Catolica de Chile
• Study coordinator: Laura A Huidobro, PhD
• Email: leahuidobro@gmail.com
• Phone: +56 9 9219 6618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

• Ultrasound in bariatric care to prevent gallstone problems

  This study tests whether preoperative gallbladder ultrasound and related imaging help identify who might benefit from preventive Ursochol after bariatric surgery.

  Recruiting Esbjerg Hospital - University Hospital of Southern Denmark · Esbjerg · NCT07453186

• Comparing Trimedat 76.95 mg orally disintegrating tablets with Trimedat 100 mg tablets in healthy adults

  This will test if Trimedat 76.95 mg dissolving tablets work the same and are as safe as Trimedat 100 mg tablets when taken fasting by healthy adults.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07421011

• Lowering insulin to reduce liver fat production

  This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.

  Recruiting Phase 1 Columbia University · New York, New York · NCT07403604

• Efimosfermin alfa for adults with liver impairment

  This trial will test a single dose of efimosfermin alfa in adults with cirrhosis-related hepatic impairment from steatotic liver disease, with and without significant alcohol use, to measure drug levels and safety.

  Recruiting at 5 sites Phase 1 GlaxoSmithKline · Rialto, California and 4 other locations · NCT07358546

• TENS to reduce anxiety, pain, and improve satisfaction after laparoscopic gallbladder removal

  This trial will try TENS (mild electrical stimulation through the skin) in adults having elective laparoscopic gallbladder removal to see if it lowers anxiety, reduces postoperative pain, and improves satisfaction.

  Recruiting Nigde Omer Halisdemir University · Niğde, Adana · NCT07307703

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.